Modified VR-CAP, Alternating with Rituximab and High-dose Cytarabine: An Effective Pre-Transplant Induction Regimen for Mantle Cell Lymphoma

Intensive first-line treatment for mantle cell lymphoma (MCL), incorporating rituximab and cytarabine followed by autologous stem cell transplantation (ASCT) consolidation for responding patients, affords high response rates and a progression-free survival exceeding 5 years. 1-3 Nonetheless, MCL remains incurable, and high-risk subsets defined by the Mantle Cell International Prognostic Index (MIPI4, 5) do not achieve the same benefit from intensified therapies.2, 6, 7 The Nordic regimen employing intensified rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (maxi-RCHOP) alternating with rituximab and cytarabine- and a version using standard RCHOP dosing-- are effective first-line regimens for MCL but do not incorporate novel, targeted agents.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 16, 2018 Category: Hematology Authors: S.D. Smith, S. Gandhy, A.K. Gopal, P. Reddy, M. Shadman, B.G. Till, R.C. Lynch, S. Kanan, A. Cowan, L. Low, B.T. Hill Source Type: research